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Abstract
Accumulation of neurofibrillary tangles (NFT), intracellular inclusions of fibrillar forms of tau, is
a hallmark of Alzheimer Disease. NFT have been considered causative of neuronal death,
however, recent evidence challenges this idea. Other species of tau, such as soluble misfolded,
hyperphosphorylated, and mislocalized forms, are now being implicated as toxic. Here we review
the data supporting soluble tau as toxic to neurons and synapses in the brain and the implications
of these data for development of therapeutic strategies for Alzheimer’s disease and other
tauopathies.
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Introduction
More than 35 million individuals currently suffer from Alzheimer Disease (AD), a
progressive neurodenegerative disorder with no known cure [1, 2]. The recent failure of
several phase III clinical trials [3] and the knowledge that the number of AD patients is
expected to double in the coming decades [4], instigates the need for a closer look at the
progress made in understanding AD and the gaps that still remain.
Since its original description in 1907, Alzheimer Disease (AD) brain has been defined by the
presence of extracellular β-amyloid (Aβ) containing plaques and cytoplasmic neurofibrillary
tangles (NFT) consisting of abnormal microtubule associated protein tau [5, 6]. These
proteinaceous aggregates are accompanied by synapse loss and neuronal cell death, which
are thought to subserve the clinical syndrome of progressive cognitive impairment in AD
[7–9]. The exact relationships and mechanisms between these four pathological hallmarks of
AD have yet to be clearly defined, though it is largely believed that the initiating pathogen is
the Aβ peptide [3, 10–14]. The strong support for the amyloid hypothesis has led the
majority of the clinical trials to date to be rather Aβ-centric [15, 16]. For some time
following the discovery of the Aβ-linked genetics of AD, no tau mutations were identified
that contributed to the disease, leading to the supposition that NFT are a downstream side-
effect of Aβ toxicity and indicative of cell death [15]. Though it is still true that no
mutations of tau have been linked to AD, a number of dementias known as tauopathies are
known to result from alterations to the tau gene [17, 18] suggesting that changes in the tau
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protein are, in fact, sufficient to induce neurodegenerative processes. Furthermore, tau
pathology correlates more closely than amyloid burden to neuronal loss, synaptic deficits
and severity of disease and cognitive decline in AD [19–21]. These findings reinvigorated
the investigation of tau as a pathologic entity in AD, ultimately leading to several clinical
trials for tau-targeted therapies [2, 15]. In more recent years it has been shown that tau is a
necessary mediator of Aβ toxicity [22–26] spurring the suggestion that AD may have
several phases, first Aβ-dependent and then Aβ-independent but rather potentially tau
dependent [27]. If this is the case, it is of course important to continue discovering Aβ
mediated mechanisms of neurotoxicity and developing appropriately targeted therapeutics,
but even more important is furthering our understanding of the mechanisms by which tau
contributes to AD in order to develop complementary tau-targeted therapies.
Biology of Tau
Tau is a microtubule-associated protein encoded by the MAPT gene on chromosome 17.
Alternative splicing of 16 exons yields six isoforms of human tau that differ in number of
amino acids (352–441), in number of N-terminal inserts (0–2N) and in number of
microtubule binding domains (3R or 4R). In normal adult brain, the ratio of 3R:4R tau is ~1
and in AD this ratio is shifted toward excess 4R tau [1, 18]. Many of the tau mutations
leading to dementia alter the splicing of the tau protein also increasing the presence of 4R
tau [18, 28]. The number of microtubule binding domains in tau determines the affinity for
microtubules (3R < 4R), thereby mediating the primary function of tau in stabilizing axonal
microtubules and enabling their polymerization and assembly [4, 28]. As microtubules serve
as the highways for trafficking of molecules within the axon, this places tau as a central
player in neuronal transport and therefore function [29]. Also contributing to the
microtubule stabilizing capacity of tau are post-translational modifications, particularly
phosphorylation, which when elevated decreases affinity of tau for microtubules and causes
it to detach [4, 18]. Tau has over 80 phosphorylation sites, some of which are considered
physiological while others are ‘de-novo’ phosphorylated in disease states [30]. Two families
of protein kinases contribute to tau phosphorylation, those that are proline directed and tend
to phosphorylate serine and threonine motifs outside the microtubule binding domain and
those that are KXGS-motif and non-proline directed and tend to phosphorylate within the
repeat domain [14, 31]. Proline directed kinases that phosphorylate tau include GSK3β,
MAPK (mitogen activated protein kinase), JNK (c-Jun N terminal kinase) and cyclin-
dependent kinase 5 (Cdk5) and have been the target of some of the preliminary tau-targeted
therapies [14–16, 18]. Kinases targeting KXGS and other non-proline motives include
microtubule affinity regulating kinase (MARK), P70S6K, BRSK, PKA and CaMKII [14,
28], with MARK recently being implicated as a critical mediator of both Aβ and tau toxicity
[26]. In physiological conditions the activities of the kinases are dynamically
counterbalanced by the primary tau directed protein phosphatases PP2A and PP1 [18, 28].
Pathological forms of tau
In disease states such as AD, it is thought that the balance of kinase and phosphatase activity
is shifted, creating a hyperphosphorylated species of tau [1, 28]. This increases the fraction
of tau that is no longer attached to microtubules, allowing for monomeric
hyperphosphorylated tau to bind one another to produce oligomers [32–34]. These
oligomers are missorted from the axonal to somatodendritic compartment [35–37], where
they undergo further hyperphosphorylation and conformational change and take on a beta-
sheet structure that is considered insoluble. Fusion of these oligomeric species contributes to
the formation of paired helical filaments (PHF), the primary constituent of NFT [28, 38–40].
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As is the case with other proteins involved in neurodegenerative diseases, the question of
which variety of tau is most toxic and whether that toxicity represents a gain or loss of
function continues to be debated [11, 37, 41]. As tau progresses from normal to NFT it
passes through a loosely defined ‘soluble’ state in which the protein may be
hyperphosphorylated, mislocalized, conformationally changed and/or oligomeric but not yet
fibrillar. It is these forms of soluble tau protein that vie against NFT in the debate of
pathogenic entity in neurodegenerative disease. The toxicity of tau can be argued in several
ways 1) aggregated fibrillar tau (NFT) is toxic and causative of cell death and cognitive
decline in AD, 2) soluble species of hyperphosphorylated, misfolded tau that accumulate in
abnormal cellular compartments are toxic and NFT act as a sink for these toxic species,
implicating NFT as protective, or 3) both soluble forms of pathological tau and NFT are
toxic to cells in different ways and on different time scales. We favor the third model of
toxicity as will be discussed.
Historically, NFT were considered indicators of cell death, particularly given that their
progression and number correlate well with severity of cognitive decline in AD, while Aβ
plaque deposition does not [19–21, 42, 43]. NFT bearing neurons of human AD brain have
been shown to have abnormal quantity or distribution of molecules necessary for proper
function such as synaptic proteins [7, 37], and calcium binding proteins [44–47] and NFT
have been suggested to interfere with basic cell function as they serve as a physical
disruption or space occupying lesion [28, 29]. In a mouse model of tauopathy, expression of
an aggregation prone tau molecule causes morphological and functional deficits while
expression of a similar but anti-aggregation tau molecule has no such negative consequences
[39, 48, 49]. NFT toxicity is also supported by cell culture models in which tau aggregation
leads to activation of caspase cascades and cell death [18].
Significant data, however, have also accumulated for the contrarian view that NFT may be
silent bystanders, thereby implicating soluble tau species or other pathological processes, but
in an indirect manner. Many cognitively normal individuals accumulate NFT, with
pathological changes in tau occurring as early as the age of 6 in brainstem nuclei [43]. AD is
often not diagnosed until NFT have spread throughout much of the brain [42, 50].
Frontotemporal dementias known to be caused by mutations in tau in humans, and a number
of animal models demonstrate severe neuronal cell loss and dysfunction in the absence of
overt or coinciding NFT pathology [18, 21, 28, 38, 51–53]. Several studies in a mouse
model that reversibly expresses a human mutant form of tau (rTg4510) show dissociation
between neuronal loss and NFT accumulation, particularly after suppressing the tau
transgene at which point neuronal loss stops though NFT persist and continue to accumulate
[54, 55]. Additional studies in these animals have shown that the presence of a tangle does
not alter spine density, electrophysiological function [2, 56] or ability to respond to
physiologically relevant stimuli [57] in comparison to non-tangle bearing neighboring
neurons. In fact, NFT appearance in these animals is preceded by caspase activation and
these neurons endure longer than anticipated following activation of these traditional cell
death signaling cascades [58, 59]. Emerging from these findings is a theory that NFT, rather
than representing silent markers of cell death, may serve as a protective mechanism of
sequestering toxic soluble tau species [18, 37].
Evidence for the toxicity of soluble tau species has been growing in recent years despite the
fact that it remains an ill-defined species. It is now thought that phosphorylation, localization
and conformational changes to tau are sufficient for occurrence of toxic effects and represent
a pre-tangle stage. These early alterations have been proposed as the beginning of the
pathological process of AD [35, 42, 43, 50, 60]. A large number of in-vitro studies have
shown that over-expression of tau or alterations in its phosphorylation state, localization or
conformation induce changes in calcium homeostasis, loss of dendritic spines, impaired
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trafficking of organelles, particularly mitochondria, and cell death [14, 18, 28, 36, 37, 40,
60–67]. Studies in mouse models support these findings, demonstrating correlations between
soluble tau species and neuronal or synaptic dysfunction [37, 49, 52, 68–70]. A recent study
by Lasagna-Reeves et al (2011) demonstrated that injection of tau oligomers, but not
monomers or fibrils, into the brain of wild-type mice was sufficient to induce synaptic
deficits, mitochondrial dysfunction and memory impairments. Furthermore, recent studies
suggest that these soluble species of tau may be transmitted between neurons and may
contribute to or be responsible for the pathological spread of disease through the brain [43,
71–74].
Mechanisms of tau toxicity
Several molecular mechanisms may underlie the toxicity of either soluble or aggregated tau.
These include the well-established tau-induced disruptions in microtubule-based transport
(which importantly effect mitochondrial transport) and the less well understood phenomena
of tau-related calcium dyshomeostasis, synaptic dysfunction and loss, and caspase activation
(summarized in Figure 1).
Tau toxicity has largely been attributed to disruption of neuronal transport, particularly as
the main function of tau is stipulated to be maintaining microtubule stability and assembly in
CNS axons. Neurons, due to their morphological structure with extended processes and
high-energy demands, rely heavily upon regulated transport of organelles and vital materials
for cell function [75, 76]. Impairment of these transport processes has been proposed as an
early pathological phenomenon and underlying cause of neurodegenerative diseases,
including AD [13, 76–82]. Both loss and gain of function mechanisms for tau interference
with transport have been proposed, but interestingly, recent studies in tau knock out models
have shown that the loss of tau, even in its entirety, is not lethal and actually demonstrates
very mild phenotypes [41, 83, 84]. Tau over-expression in cell culture without the formation
of NFT has been shown to inhibit fast axonal transport, with mitochondria emerging as the
cargo most susceptible to deficits in localization, implicating soluble tau in these deficits
[62–68, 85, 86]. Patches of “soluble” tau bound to microtubules have been proposed to serve
as a roadblock, preferentially causing anterograde-moving kinesins to detach from the
microtubule [62]. A second theory suggests that soluble tau can interfere with transport by
directly competing with cargo or hampering signaling cascades [78, 87, 88]. Ittner et al
(2009) demonstrated that pathologically hyperphosphorylated tau directly interacts with
JIP1, a protein involved in linking cargoes to the kinesin motor, thereby preventing proper
association of cargo and motor. Other studies have suggested that tau may bind influential
molecules such as GSK3β, or mitochondria themselves to alter transport and localization of
organelles in a more indirect manner [78, 89–92]. Yet other studies have suggested that tau
itself is a kinesin cargo and when cytosolic concentration of tau is pathologically increased,
it may out compete other cargoes [63]. Aggregates of misfolded tau (NFT and neuropil
threads) have been argued to interfere with transport by serving as a space-occupying lesion,
thereby inhibiting kinesin binding and movement [85, 86].
Consequences of impaired neuronal transport due to any of the mechanisms discussed above
include altered distribution and function of organelles, particularly mitochondria, resultant
perturbations in cell function, synapse loss and dying back of the neuron ultimately leading
to cell death [78, 93]. Mitochondria have been increasingly recognized for their potential
contribution to disease pathogenesis [13, 76, 94, 95], with evidence mounting that
disruptions to mitochondrial localization and function may serve as the intersection for Aβ
and tau-mediated toxicity [1, 2, 96, 97]. Tau over-expression in cultured cells leads to
perinuclear clumping of mitochondria [63–66, 98], while application of oligomeric Aβ leads
to depletion of mitochondria, especially in distal dendrites, and this deficit is thought to be
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mediated by missorting or hyperphosphorylation of tau [14, 81, 91]. Recent evidence from
our group suggests that mitochondrial transport deficits are due in large part to soluble forms
of tau. Mitochondrial distribution in the brains of rTg4510 mice was significantly altered in
cells containing aggregates of tau at an early age and in neurites regardless of whether
aggregates of tau are present. These deficits are exacerbated with age and completely
recovered when soluble tau is reduced by transgene suppresion, even in the continued
presence of aggregated tau, pointing to the importance of soluble tau in this process [99].
We also observed deficits in mitochondrial distribution in human AD tissue in both tangle
and non-tangle bearing neurons in superior temporal gyrus [99]. Other groups have observed
similar alterations to mitochondrial localization in human AD brain, with depletion of
mitochondria from the dendritic tree and concomitant accumulation within the soma [80,
81].
Loss of proper transport processes leaves synapses depleted of mitochondria, which are
essential for the high-energy demand and frequent calcium fluxes of normal synaptic
function and could therefore contribute to synapse loss evident in AD [100]. With
distribution deficits often comes mitochondrial dysfunction, with altered electron transport
chain function and loss of ATP, damaged processing of reactive oxygen species, calcium
buffering impairments and release of molecules leading to cell death signaling cascades [13,
77, 96, 101]. A study in cultured neurons demonstrated that over-expression of tau induces
mitochondrial distribution deficits and concomitant dysfunction, but functional deficits only
emerged when challenged with thapsigargin, which results in global increase in cytosolic
calcium levels [102]. These data raise an interesting relationship between mitochondria and
calcium homeostasis. In 2009, Wang and Schwarz proved that local elevations in calcium
can arrest mitochondria along their transport route, serving as a mechanism of securing
mitochondria where they are needed. In this reciprocal relationship, calcium influences
mitochondrial localization and mitochondria play an influential role in regulating
intracellular calcium homeostasis [44, 46, 93, 103, 104].
Calcium dysregulation is another potential mechanism downstream of pathological tau
changes. Calcium signaling is thought to be critically important for learning and memory
processes, and is known to be altered in human AD brain, with the calcium hypothesis first
appearing in the late 1980s [13, 46, 103–106]. In concert with the prominence of the
amyloid cascade hypothesis, much of the understanding of calcium changes in AD has been
in relation to presence of Aβ. In-vitro studies have revealed that administration of Aβ can
induce intracellular calcium increases that are associated with subsequent spine loss [14,
107]. It is thought that Aβ peptides can create holes within the plasma membrane, creating a
non-specific cation channel, permitting calcium to pass through easily. Ion channel function
can also be altered by Aβ presence, including those at synaptic sites such as NMDA and
AMPA receptors, and within membranes of internal calcium stores such as at the
endoplasmic reticulum and mitochondria [44, 103, 104, 108]. Studies in APP/PS1 mice that
have altered Aβ production and develop plaque pathology show distinct calcium overload in
neurites surrounding plaques in-vivo [109]. Much less is understood about calcium
dynamics and homeostasis and tau, though recently calcium dysregulation has been
proposed as another potential cellular mechanism upon which Aβ and tau toxicity may
converge [2]. Electrophysiological studies in mice over-expressing a human mutant form of
tau support a role for elevated calcium levels in pathology [56, 110]. Mutations of tau that
lead to frontotemporal dementia have been shown to alter function of voltage gated calcium
channels [45] and recent studies have placed physiological tau at the dendritic spine, as a
crucial mediator of normal NMDA receptor stability and function [22, 30, 69]. Tackenberg
& Brandt (2009) reported that blockade of NMDA receptor activity was sufficient to prevent
tau toxicity. When tau is pathologically missorted in this scenario, the NMDA receptor is
susceptible to damage or altered function. This may serve as a potential patho-mechanism in
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which tau contributes to Aβ toxicity [22–24, 26, 111]. Interestingly, one of the few FDA
approved treatments currently prescribed for AD targets the NMDA receptor [1, 2, 32].
Other receptors have also been implicated, as extracellular application of tau to cells in
culture has shown to elevate intracellular calcium levels, but purportedly through muscarinic
receptors rather than NMDARs [74].
Evidence from in vivo multiphoton imaging studies suggests that in rTg4510 tau
overexpressing mice, membrane integrity is disrupted in a small subset of neurons [112],
which could cause disruptions in cellular calcium levels. This disruption is coincident with
caspase activation, which precedes tangle formation, and both caspase activation and
membrane disruption resolve after tangles form [112, 113], implicating soluble tau as toxic
to membranes and potentially causative in disrupting calcium homeostasis. Normal cell
function requires tight regulation of calcium dynamics, so disruption of these processes can
have significant deleterious effects, including disrupted transport, altered signaling cascades,
mitochondrial dysfunction, synaptic deficits and even cell death [104].
Dendritic spines and synapses are especially vulnerable to changes in either calcium
homeostasis and mitochondrial distribution or function [44, 46, 75, 80, 82, 114, 115].
Synapse loss is the leading correlate to cognitive decline in AD [7, 8, 116], correlating more
closely even than NFT [19–21], and yet the mechanism of synaptic degeneration in AD and
other tauopathies is not clearly understood and rather controversial. Reports of synapse loss
in tau models vary dramatically with some studies suggesting negligible or no spine loss [38,
60, 69, 88], others demonstrating significant synaptic deterioration [10, 14, 39, 49, 56, 67]
and others still indicating increases in synapse density, potentially serving as a
compensatory mechanism [89, 110, 111, 117]. Dysregulation of synaptic protein levels in
homogenates from a number of tau mouse models have been demonstrated with or without
associated synapse loss in the same model [39, 69, 92, 96]. Synapse loss and dysfunction are
argued to precede neuronal loss and NFT accumulation with decreased expression of some,
but not all, synaptic markers [69, 70]. These and other data argue that synaptic deficits occur
in an NFT-independent manner, again making the case that soluble tau serves as the toxic
entity [51, 52, 56, 70, 92, 118]. Kimura et al (2010) suggest that tau aggregates induce
neuronal, but not synapse loss while hyperphosphorylated species of tau are associated with
decreased expression of synaptic proteins. Work from the Mandelkow group, however,
suggests that it is the amyloidogenicity of tau that induces spine loss, arguing that it is the
aggregates that are detrimental to synapse density and function [35, 39, 48, 49].
Implications for therapeutic strategies
Given the considerable evidence for each argument in the debate of NFT versus soluble tau
toxicity, it remains unclear which species of tau is truly the culprit. As a result, tau targeted
therapeutics vary significantly in their targets and approaches. Inhibiting or reversing tau
aggregation has been one of the most avidly pursued and more promising avenues of tau
targeted therapies to date [1, 16]. Methylene blue, a member of the phenothiazine family
used historically for treatment of other human diseases, has been shown to prevent tau
aggregation in vitro [119] and progressed to phase II clinical trial in human AD patients with
promising results [1, 2, 84, 120]. Several studies in mouse models of tauopathy have
indicated that immunization with a late stage tau phospho-epitope can dramatically reduce
tau aggregation and improve cognitive impairments [121–123], suggesting this may serve as
a viable opportunity for clinical trial. Continued screens for other compounds that can
reverse or inhibit tau aggregation have yielded several promising candidates including
anthraquinones, n-phenylamines and rhodanines that have yet to be thoroughly evaluated [1,
16, 124]. However, it should be noted that if NFT are not the detrimental tau species,
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therapies targeted at decreasing their aggregation could in fact be contributing to disease
pathogenesis if soluble tau levels are not also decreased by these treatments.
The predominant means by which it is thought that pathological changes in tau may disrupt
axonal transport, is via destabilization of microtubules, leading to their disassembly [11, 29].
Based on this reasoning, microtubule stabilizing drugs have been suggested as therapeutic
agents for AD, with one reaching clinical trial [1–3, 14, 84, 107]. Zempel et al (2010)
demonstrated that application of taxol to cells in culture can allow for recovery of
microtubule density, mitochondrial localization, missorting of tau and loss of spines, though
calcium changes and hyperphosphorylation of tau persisted. Treatment of tau transgenic
mice with microtubule stabilizer paclitaxel generated improved axonal transport and motor
phenotype [16, 125, 126]. A peptide (NAPVSIPQ) with better blood brain barrier
permeability but similar microtubule stabilizing capabilities yielded comparable results in
mouse models [16, 127–129] and recently completed Phase II clinical trial with evidence of
improved performance on several of the memory tasks [3, 130]. Though promising,
unfortunately, microtubule stabilizers often have significant side effects and suffer from
having poor blood brain barrier permeability, so other methods of influencing microtubule
stability continue to be explored [15, 16].
Since aberrant tau phosphorylation is thought to be a crucial mediator of affinity of tau for
microtubules and a critical step toward tau-induced toxicity, significant effort has been
directed toward developing kinase inhibitors or phosphatase activators that can modulate
this process. Lithium (LiCl), which is a GSK3β inhibitor used for treatment of human
psychiatric conditions, has been linked to behavioral improvements in tau mice that are
associated with decreased levels of insoluble and hyperphosphorylated tau. Similar findings
resulted from treatment of tau mice with sodium selenate, but via a PP2A dependent
mechanism leading to dephosphorylation of tau [1, 16]. Developing kinase inhibitors or
phosphatase activators that are both selective and without significant side effects, however,
is not trivial as they have many targets and are involved in many signaling cascades [16].
Other post-translational modifications of tau and tau degradation pathways have also been
tested as preliminary targets for tau therapeutics [2, 16, 84], but stand much further from
clinical trial. In addition, since tau reduction or elimination has been shown to ameliorate
Aβ-induced toxicity [23–25] it is, therefore, now being pursued as a therapeutic mechanism
[84]. To date, three tau-targeted therapeutics have reached clinical trial - kinase inhibitor
LiCl, tau aggregation inhibitor methylene blue and microtubule stabilizer NAP [16, 84], yet
the mechanism of tau toxicity continues to be clearly defined. With better understanding of
the species of tau that is detrimental to neuronal function and morphology, and the manner
in which it exerts its toxicity, comes a wealth of new potential therapeutic targets.
Based on the evidence that mitochondrial transport deficits caused by tau-induced transport
failure may interfere with mitochondrial function, therapeutics targeting mitochondrial
processes may prove advantageous. Antioxidants have long been mentioned as beneficial for
potential prevention and treatment of AD [1, 2, 97]. Though unlikely to serve as a stand-
alone cure, alleviating mitochondrial stress in conjunction with Aβ and tau therapies may
prove useful. Similarly, calcium buffering or stabilizing compounds have also been
suggested [47, 131]. It is via this mechanism that exercise is argued to benefit neuronal
health, by increasing neurotrophic and neurogenic factors in the brain, which are efficient at
stabilizing calcium changes [44, 47]. Further understanding of the newly proposed dendritic
function of tau, both physiologically and pathologically, along with other lesser-known
functions of tau may generate new, more effective, therapeutic targets [4, 18, 28, 29].
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Conclusions and Future directions
The studies discussed here show that there is evidence for both soluble
(hyperphosphorylated, misfolded, and mislocalized) and fibrillar tau contributing to
neuronal and synaptic dysfunction and loss. On balance, there is very little direct evidence
that tau fibrils themselves are toxic, thus we favor the hypothesis that soluble forms of tau
are more toxic to neuronal function (mitochondrial trafficking, calcium regulation, etc) and
synaptic function (electrophysiological deficits and dendritic spine loss) and ultimately
contribute to synaptic and neuronal degeneration. In this model, we hypothesize that soluble
forms of pathological tau induce neuronal transport deficits, synaptic dysfunction, caspase
activation, and membrane disruptions, which may contribute to dying back of denervated
processes and neuronal death. Formation of tangles may protect neurons acutely from the
effects of toxic soluble tau, as seen in vivo by the caspase activation that precedes tangle
formation that resolves after NFT form [112]. The strong evidence implicating soluble tau as
toxic does not preclude a toxic role for NFT also. Long-term, further inhibition of cellular
transport by NFT and neuropil threads acting as space-occupying lesions may lead to slower
cell death, or NFT may reach “capacity” unable to further absorb soluble tau which
continues to accumulate and causes cell death as outlined above. These NFT-bearing
neurons may then then die more slowly leaving the ghost tangles observed in Alzheimer
patient brains.
Future studies are needed to confirm these hypotheses about the toxicity of soluble vs
fibrillar tau and the molecular mechanisms of toxicity. In vivo multiphoton imaging
provides a powerful tool for addressing these issues of causality and temporal progression of
disease. We have observed cell death over the course of days in YFPxrTg4510 mice
occurring at a rate of approximately 2% per week (Figure 2) using cranial window
implantation and multiphoton imaging of YFP as described previously [132]. This is similar
to the 4.6% loss of yfp cells per month reported in living 3XTg mice that express mutant
amyloid precursor protein, mutant tau, and mutant presenilin [10], but technical limitations
have thus far prevented concurrently imaging whether NFT or hyperphosphorylated,
misfolded tau are present in soma that are dying. Future studies may overcome this
limitation by introduction of strong NFT labeling fluorophores by adsorption onto
nanoparticles which can carry molecules across the blood-brain-barrier [133].
Taken together, these studies implicate soluble species of tau, rather than aggregates, as
more detrimental to neuronal morphology and function. The idea that NFT may serve as a
silent or potentially protective mechanism of sequestering soluble tau is supported by these
studies. The presence of a tangle may indicate that the neuron has reached a threshold for
soluble tau, initiating a compensatory mechanism that ultimately is unable to save the cell.
These data also suggest that therapeutics aimed at preventing or reversing tau aggregation
may, in fact, prove deleterious by increasing the concentration of toxic soluble tau species.
Tau reduction mechanisms may prove a more promising avenue to pursue.
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Figure 1.
Mechanisms of tau toxicity. Strong evidence supports a role of soluble pathological forms of
tau in several mechanistic pathways leading to synapse and neuronal death. Tau is normally
largely bound to axonal microtubules and plas a role in dendritic spine plasticity. During
Alzheimer’s disease and other tauopathies, tau becomes hyperphosphorylated and
misfolded. It detaches from microtubules and accumulates in the somatodendritic
compartment. Accumulation of soluble tau in the soma is associated with caspase activation
and disruptions of membrane integrity, which resolve after the soluble tau coalesces into a
neurofibrillary tangle. Removal of tau from microtubules causes them to degenerate, and
pathological tau may also directly interfere with microtubule based transport mechanisms.
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Disturbances in microtubule transport affect mitochondrial trafficking to distal parts of the
neuron resulting in perinuclear clumping. Synapses become dysfunctional and dendritic
spines are lost, and calcium levels increase in dendrites with accumulations of soluble tau.
Synapse loss and the inability to energetically maintain axons are thought to contribute to
the dying back of processes and cell death.
Kopeikina et al. Page 17
Transl Neurosci. Author manuscript; available in PMC 2013 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2.
Cell death in tauopathy model mice. In vivo multiphoton imaging of neurons in mice
expressing yellow fluorescent protein and P301L mutant tau (YFPxrTg4510 line) in
pyramidal neurons undergo cell death (asterisk indicates a cell that died between one day
and the next). Postmortem staining (bottom) confirms that YFP expressing neurons also
express human tau in this model. Neuronal death is halted by transgene suppression in
rTg4510 mice without removing existing tangles [54], and caspase activation, which occurs
in neurons before NFT form, is turned off after tangle formation [113], both implicating
soluble tau in cell death. However, the forms of tau present in dying neurons have not yet
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been elucidated. Scale bars 50 µm. Thanks to Rose Pitstick and George Carlson for mouse
breeding and genotyping.
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